Skip to main
DTIL
DTIL logo

Precision Biosciences (DTIL) Stock Forecast & Price Target

Precision Biosciences (DTIL) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Precision BioSciences Inc. is experiencing positive developments with its ARCUS genome editing platform, as evidenced by the successful progression of its partnered programs, which enhance its clinical potential across diverse disease settings. The company has two wholly-owned ARCUS-based programs that are gaining momentum backed by partner-led clinical validation, indicating strong advancements in their pipeline. Notably, preclinical results show treated mice achieving up to 93% of maximum force output and a 66% improvement in resistance to eccentric injury, suggesting significant therapeutic efficacy and reinforcing confidence in the platform's capabilities.

Bears say

Precision BioSciences Inc. has experienced a notable decrease in revenue, with cash and cash equivalents falling to approximately $100 million from the previously estimated $122 million. This decline is attributed to reduced revenue recognition from collaborations with Prevail/Lilly and Novartis, as both agreements progress towards conclusion and affect short-term financial contributions. Furthermore, the company’s reliance on a recent license agreement with TGTherapeutics for CAR T therapy indicates a dependency on external partnerships for sustaining revenue, raising concerns about long-term financial stability.

Precision Biosciences (DTIL) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Precision Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Precision Biosciences (DTIL) Forecast

Analysts have given Precision Biosciences (DTIL) a Buy based on their latest research and market trends.

According to 2 analysts, Precision Biosciences (DTIL) has a Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Precision Biosciences (DTIL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.